Following the confirmation of the first case of Covid-19 in Wuhan, China, in November 2019, the virus has rapidly spread worldwide. Hence, the World Health Organization (WHO) declared the outbreak a global pandemic (
1). In general, coronavirus expresses four different structural proteins: envelope (E), membrane (M), nucleocapsid (N), and spike (S). Spike protein is related to binding and entry into the host cell. The spike consists of S1 and S2, which attach to the ACE2 receptor of the target cell with S1 (
2,
3). Since the onset of the Covid-19 pandemic, various mutations in different parts of the viral genome have been identified in several countries. Some of these mutations resulted in an increased infection rate or changed the pathogenicity. Tens of thousands of SARS-CoV-2 variants differ in at least one conversion (
4). Due to the crucial effects of mutations in all stages of the infection (ie, from prevention to treatment), identification and examination of viral variants are critical health approaches in every country. Some variants are less detectable by the reverse transcription-polymerase chain reaction (RT-PCR) technique. It can also be crucial for future decisions, such as complying with lockdown or implementing health protocols and deciding how to control and deal with the virus. Type and manner of usage of drugs, such as the time and dose of drugs, can vary in different variants (
5). Dealing with a virus with other structures is the most critical issue in vaccine design because the previously produced vaccines may not be able to fight the new form of the virus genome. Moreover, the SARS-CoV-2 genome mutations vary in different countries, and one type of vaccine may not be helpful in all countries (
6,
7). However, the evaluation and identification of mutated virus strains in each region can effectively aid in disease prevention and enforcing health policies in that country.